Loss of heterozygosity (LOH) at chromosome 10q23-q25 is frequent in small cell lung cancer (SCLC), indicating the presence of putative tumor suppressor genes. PTEN/ MMAC1, a newly cloned candidate tumor suppressor gene at 10q23, was mutated in multiple human cancers. We investigated whether mutations of PTEN/MMAC1 play an important role in SCLC tumorigenesis. We examined 16 SCLC cell lines for PTEN/MMAC1 mRNA expression by reverse-transcriptase polymerase chain reaction (RT ± PCR) and potential mutations by sequencing analysis of the PTEN/MMAC1 coding region. No mutation was observed in PTEN/MMAC1 cDNAs in 15 cell lines expressing PTEN/MMAC1. One SCLC cell line, DMS79, did not have detectable PTEN/ MMAC1 expression. Importantly, we identi®ed a novel homologue of PTEN/MMAC1, termed PTH2, localized to chromosome 9p21-q13 and containing only ten amino acid substitutions compared with the PTEN/MMAC1 coding region. However, because the putative initiation codon for PTEN/MMAC1 gene was changed to arginine in PTH2, the translational initiation site of PTH2 is very likely to dier from that of the PTEN/MMAC1. PTH2 was expressed in two normal lung tissues and two normal colon tissues, but in only four of 16 SCLC cell lines. A missense mutation in PTH2 was identi®ed in a SCLC cell line that did not express PTEN/MMAC1 mRNA. Our data suggest that inactivation of PTEN/ MMAC1 is a rare event in SCLC tumorigenesis. However, the PTEN/MMAC1 homologue PTH2 may play a role in SCLC tumorigenesis.
Introduction
Lung cancer is the leading cause of cancer death in the United States (Parker et al., 1997) . Small cell lung cancer (SCLC) accounts for more than 20% of lung cancers, and this tumor type carries an extremely poor prognosis (Parker et al., 1997) . SCLC is believed to develop in a multistep process in which genetic alterations, including oncogenes and tumor suppressor genes, accumulate. Inactivation of tumor suppressor genes plays an important role in this process and involves loss of one of the alleles and mutations in another allele of the genes (Nowell, 1976; Fearon and Vogelstein, 1990) . Loss of heterozygosity (LOH) was frequently observed on multiple chromosome loci in SCLC (Hosoe et al., 1994; Merlo et al., 1994a; Mori et al., 1990; Miller et al., 1992) . Several candidate tumor suppressor genes located on these chromosome loci were identi®ed, such as the FHIT gene (Ohta et al., 1996a) , the RB gene (Mori et al., 1990) , and the p53 gene (Zakut-Houri et al., 1983; Matlashewski et al., 1984) . However, other potential tumor suppressor genes that may play roles in SCLC have not yet been found. For example, 9p is one of the most frequently deleted chromosome arms in SCLC (Kim et al., 1997) , and alterations of p16 gene (9p21), which is inactivated frequently in many tumor types, are not often observed in SCLC (Otterson et al., 1994; Kelley et al., 1995) , suggesting the presence of other yet to be identi®ed tumor suppressor genes on 9p.
Recently, we found that at least two tumor suppressor genes may be presumed present on 10q24-q25 in SCLCs (Kim et al., manuscript submitted) . A candidate tumor suppressor gene called PTEN/ MMAC1 (phosphatase and tensin homologue deleted on chromosome 10/mutated in multiple advanced cancers 1) located at 10q23 was recently identi®ed by positional cloning strategy, and mutations of the gene were found in a number of cancer cell lines and primary tumors of glioblastoma and in prostate, kidney, and breast carcinomas (Li et al., 1997; Steck et al., 1997) . Our deletion mapping data suggest a minimally deleted region at 10q24 (Kim et al., manuscript submitted) which is about 17 cM telomeric to the PTEN/MMAC1 gene in SCLCs. This suggested that another tumor suppressor gene besides PTEN/ MMAC1 may be present, but in many of our SCLCs a larger area including the PTEN/MMAC1 gene was deleted (data not shown). To test whether mutations of the PTEN/MMAC1 gene play an important role in SCLC, we studied 16 SCLC cell lines for potential alterations in the gene. Except that one cell line did not express PTEN/MMAC1, no abnormality was found involving the gene. Furthermore, we identi®ed a homologue of PTEN/MMAC1, termed PTH2, which is not expressed in 75% SCLC cell lines, and localized it to chromosome 9p21-q13.
Results

Mutation of the PTEN/MMAC1 is rare in SCLC cell lines
To test whether the PTEN/MMAC1 gene plays an important role in SCLC, we sequenced the entire coding region of PTEN/MMAC1 for potential muta-tion of the gene and found no mutation and sequence variation in the 15 SCLC cell lines we examined. One SCLC cell line, DMS79, did not have detectable PTEN/MMAC1 expression. Because of the presence of a PTEN/MMAC1 homologue, which was coampli®ed with PTEN/MMAC1, the evidence of no PTEN/MMAC1 expression was the lack of speci®c PTEN/MMAC1 sequences in ampli®ed cDNA by direct sequencing analysis. Southern blot analysis using a full-length PTEN/MMAC1 cDNA probe failed to ®nd an abnormality in DMS79 cell line (data not shown), suggesting that gross deletion of the gene may not be the reason for the abnormal expression of the gene.
Identi®cation of PTH2, a homologue of PTEN/MMAC1
When sequencing cDNA fragments ampli®ed using primers 1S, 1AS, 2S, and 2AS, we found sequences distinct from published PTEN/MMAC1 cDNA sequences by 18 nucleotides in some SCLC cell lines ( Figure 1a ). Some of these variations do not cause amino acid change, but others resulted in a total of ten amino acids changes in this novel sequences (Figure 1b ). These variants cannot be explained by sequence variations (polymorphism) of the PTEN/ MMAC1 gene because the variations involved too many sites and caused too many amino acid changes. To determine whether the variations were produced by a PTEN/MMAC1 homologue, we designed a set of PCR primers (PTH2S1 and PTH2AS1) speci®c for the new sequences and used them to amplify a predicted 107 bp genomic DNA fragment. Using a radiation hybrid panel, this fragment was mapped to chromosome 9, close to microsatellite marker D9S1878. D9S1878 is located at about 58 cM from the top of chromosome 9 and between the frame markers D9S165 (top) and D9S15 (bottom). D9S165 was mapped between 9p21 and 9q21 and 2 cM north of D9S1878, while D9S15 was mapped between 9q13 and 9q21 and 2 cM south of D9S1878. Therefore, this fragment should be located between 9q21 and 9q13. Because the PTEN/MMAC1 gene is located at 10q23, the localization of the novel fragment to chromosome 9 demonstrated that this is a novel gene with extremely pronounced homology to PTEN/MMAC1. Because of this high degree of homology to PTEN/ MMAC1, we named it PTH2, for phosphatase and tensin homologue 2.
Because the two genes are so similar, it was possible that PTH2 was a pseudogene derived from PTEN/MMAC1. To exclude this possibility, we carried out polymerase chain reaction (PCR) using genomic DNA as the template and 2S and 2AS as the primers and could not obtain a PCR product (data not shown). We further ampli®ed synthesized cDNAs from SCLC cell lines (including DMS79, which expressed only PTH2 sequences, and NCI-H146, which expressed both PTEN/MMAC1 and PTH2 sequences) and their corresponding negative controls (cDNA synthesis using the same RNA templates without reverse transcriptase) using the primers 2S and 2AS. The expected 1146 bp PCR products were seen only in samples using reverse transcriptase (RT) in cDNA synthesis and not seen in any of the negative controls ( Figure 2a ). To determine whether PTH2 was expressed in uncultured tissues, we examined two normal lung tissues and two normal colon mucosa samples using RT ± PCR and sequence analysis. PTH2 was expressed in all four samples tested (Figure 2b ). These data indicate that PTH2 was indeed transcribed, at least in normal lung tissues and colon mucosa.
Mutation and expression of PTH2 in SCLC cell lines
As described, DMS79 cell line expressed only PTH2 but not PTEN/MMAC1. Interestingly, a missense mutation of PTH2 was identi®ed in this cell line at codon 278 (TTC to TTG transversion), causing an amino acid change from phenylalanine to leucine (Figure 3a) . Because no corresponding normal tissue of this cell line was available, we could not exclude the possibility that this nucleotide variation was a polymorphism. Functional analysis will be necessary to determine the signi®cance of this alteration. However, the complete nucleotide substitution in the sequencing gel (Figure 3a) indicates either one copy of the PTH2 gene was deleted or a wild-type copy of the gene was not expressed. Among 16 SCLC cell lines studied, four (DMS79, NCI-H146, NCI-H82, and NCI-H524) (25%) expressed detectable PTH2 by RT ± PCR sequencing analysis, and one of the four contained a putative point mutation of the gene (DMS79). Therefore, only three SCLC cell lines (19%) actually expressed wild-type PTH2 (Figure  3b ), suggesting that PTH2 may play a role in SCLC.
Discussion
PTEN/MMAC1 gene was recently cloned and suggested as a promising candidate tumor suppressor. Indeed, mutations of the PTEN/MMAC1 gene were found in a number of glioblastoma cell lines and primary glioblastomas and also in such cancer cell lines as prostate, kidney, and breast carcinomas (Li et al., 1997; Steck et al., 1997) . Recent cytogenetic studies indicated that loss on 10q is also frequent in SCLCs (Ried et al., 1994; Petersen et al., 1997) . By analysing a large number of primary SCLCs using intensive microsatellite markers in 10q23-q26, we recently observed two distinct minimally deleted regions on 10q in this tumor type (Kim et al., manuscript submitted) . Although the minimally deleted regions were away from the PTEN/ MMAC1 gene, LOH might extend to or include the PTEN/MMAC1 gene region in a considerable portion of the SCLCs tested (data not shown). However, the lack of mutation or deletion of the PTEN/MMAC1 gene in SCLC cell lines indicates that genetic alteration of the PTEN/MMAC1 gene is uncommon in this tumor type. The lack of detectable expression of the PTEN/ MMAC1 in DMS79 cell line without gross genomic abnormality of the gene suggests that other mechanisms such as mutations at splice sites or methylation of the promoter region of the gene may play a role. These ®ndings support the notion that tumor suppressor genes other than PTEN/MMAC1 may be present in this region and may play an important role in SCLC.
It was suggested that the PTEN/MMAC1 gene might encode a cytoplasmic protein tyrosine phosphatase (PTPase) because its predicted protein has a signi®cant homologue to the core motif of PTPase (Steck et al., 1997) . In comparing the amino acid sequences of PTEN/ MMAC1 and PTH2, we noticed several important factors. The putative initiation codon of PTEN/ MMAC1 was changed to arginine in PTH2 ( Figure  1b) . The PTH2 gene, therefore, could be translated at codon 35, a methionine with an almost Kozak initiator (GCTATGGG) (Figure 1a ) (Kozak, 1986) . This potential initiation site may produce a predicted protein lacking 34 amino acids at the N-terminal. Alternatively, the translation of PTH2 may initiate upstream of this arginine codon and produce a protein with additional amino acids at the N-terminal. The PTEN/MMAC1 gene has a large (41 kb) 5' untranslated region, as does the PTH2 gene (at least 500 bp). Some nucleotide changes have been revealed in the region of the PTH2 gene (data not shown); it therefore seems likely that translation of PTH2 occus upstream and produces additional amino acids at the N-terminal. This possibility is currently under investigation. The catalytic domain of the PTPase in PTEN/MMAC1 is conserved exactly in PTH2 (Figure 1b ), suggesting that PTH2 may also be a cytoplasmic PTPase. The two identical tyrosine phosphate acceptor sites are also highly conserved between the two predicted proteins (Figure 1b) , suggesting their potential roles in tyrosine phosphate signaling. However, some amino acid substitutions, especially a proline at codon 30 changed to a leucine, may alter the con®guration of PTH2 to a threedimensional structure distinct from PTEN/MMAC1. It is interesting to map the PTH2 gene to chromosome 9. The short arm of chromosome 9 is frequently deleted in many types of human cancer, including SCLC and non-small cell lung cancer (NSCLC) (Kim et al., 1997; Merlo et al., 1994a, b) . Although the p16 tumor suppressor gene located at 9p21 is inactivated in many human cancers (Nobori et al., 1994; Kamb et al., 1994; Merlo et al., 1995; Cairns et al., 1995) , the presence of other tumor suppressor genes in chromosome 9 has been suggested (Kim et al., 1997; Ohta et al., 1996b; Wiest et al., 1997) . In fact, many lung cancers may have lost a whole chromosome 9 (Merlo et al., 1994a and 1994b) . Our recent study revealed at least three distinct minimally deleted regions at 9p in SCLCs (Kim et al., 1997) , and one of the regions is close to the region of the PTH2 gene. LOH analysis of primary SCLCs using extensive microsatellite markers close to PTH2 should provide further information. These data suggest the presence on chromosome 9 of other tumor suppressor genes that may play important roles in lung cancer, especially SCLC. The rare alterations of PTEN/MMAC1, the high similarity of the PTH2 and PTEN/MMAC1 genes, a putative point mutation of PTH2 in a SCLC cell line, and the undetectable expression of PTH2 in most of the other SCLC cell lines examined in this study all suggest that PTH2 is a candidate tumor suppressor gene and that it may play a role in lung cancer tumorigenesis.
Materials and methods
SCLC cell lines and normal tissues
Sixteen SCLC cell lines were used in this study. Five (DMS79, NCI-H378, NCI-H209, NCI-H82, and NCI-H146) were obtained from American Type Culture Collection (ATCC), and the other eleven (NCI-H1926, NCI-H1045, NCI-H1092, NCI-H2122, NCI-H2141, NCI-H2171, NCI-H889, NCI-H526, NCI-H345, NCI-H187, and NCI-H524) were kindly provided by Dr John Minna of The University of Texas Southwest Medical Center in Dallas. The cell lines were cultured in 90% RPMI 1640 and 10% fetal bovine serum in the presence of 5% CO 2 at 378C. Two normal lung tissue samples were obtained from two patients who underwent lung lobectomy because of lung cancer or metastatic osteosarcoma. Two normal colon tissue samples were taken from normal mucosa distant to primary colon carcinoma (also from two patients). Those samples were collected after surgery and stored at 7808C until the experiment.
RNA extraction and RT ± PCR
Most of the cell lines grew in suspension, and a few cell lines grew in monolayer attached form. After growing to appropriate numbers, cells were collected and washed with PBS. About 5 ± 10 6 10 6 cells were subjected to total RNA extraction using RNAzol (Life Technology, Gaithersburg, MD) and following the manufacturer's protocol. About 30 mg of fresh normal tissue per sample was immediately added into a 1.5 ml plastic centrifuge tube with 1 ml RNAzol and homogenized using a homogenizer (Fisher Scienti®c, Pittsburgh, PA). Total RNA was extracted according to the manufacturer's protocol. For RT ± PCR, a 2 mg total RNA was subjected to reverse transcription with random hexamer, dNTPs, and 200 units Superscript II RNase H 7 RT (GIBCO BRL, Gaithersburg, MD) in a 20ml reaction volume. PCR ampli®cation was performed by using primers 1S (5'-GAGTCGCCTGTCACCATTT-3') and 1AS (5'-TTCC-AGCTTTACAGTGAATTG-3') and 2S (5'-TGGGATT-TCCTGCAGAAAG-3') and 2AS (5'-TTTTCATGGTGTTTTATCCCTC-3') for two overlapped fragments covering the whole coding region of the PTEN/MMAC1 cDNA.
Sequence analysis
Ampli®ed cDNA fragments were puri®ed by phenolchloroform extraction and ethanol precipitation. Puri®ed DNA was subjected to sequence analysis as described previously (Kim et al., 1996) . Brie¯y, DNA templates and sequencing primers including 1S, 1AS, 2S, 2AS, 4S (5'-GAAGATCTTGACCAATGGC-3'), 5S (5'-GAAGTAAG-GACCAGAGAC-3'), 6S (5'-GGAAGTCTATGTGAT-CAAGA-3'), 6AS (5'-TCTTGATCACATAGACTTCC-3'), and 7AS (5'-TTGACGGCTCCTCTACTG-3') labeled with g-33 P-ATP were ampli®ed by PCR for 30 cycles using the AmpliCycle sequencing kit (Perkin-Elmer, Branchburg, NJ) according to the manufacturer's protocol. Each ampli®ed product (3 ml) was run on a 6% long-range gel (FMC BioProducts, Rockland, ME) and exposed to ®lm. Each alteration identi®ed was con®rmed by a repeat sequence analysis.
Radiation hybrid mapping
A Standford G3 radiation hybrid panel (Research Genetics, Huntsville, AL) was used for mapping the chromosome location of PTH2, PTH2-speci®c PCR primers PTH251 (5'-GGACCCACACGATGGGAG-3') and PTH2-AS1 (5'-AGCATCTTGTTCTGTTTGTGG-3'), which were designed to amplify the speci®c gene, were used to screen the 83 clones in the radiation hybrid panel. The data were analysed by a chromosome localization server (http://shgc-www.stanford.edu) to calculate the possible chromosome location of the gene.
